October 21, 2021
Aon Life Sciences Advisor
Top Stories
A study published in JAMA Internal Medicine showed Medicare has spent almost $600 million over three years on cancer treatments approved under the FDA's accelerated review pathway that were later found to offer no clinical benefit and did not improve overall survival in patients with breast, lung, urinary tract and liver cancers. Researchers said the findings underline the need to reform the FDA's accelerated approval program "so that the benefits of early access are better balanced with the downsides of spending large sums of money on drugs without clinical benefit."
Full Story: United Press International (10/18) 
LinkedIn Twitter Facebook Email
Liability and Safety
A recall of two COVID-19 laboratory test kits from Abbott Molecular, an Abbott Laboratories unit, has been identified as Class 1 by the FDA due to the tests' potential for false positives. The recall is for the Alinity m Resp-4-Plex AMP and the Alinity m SARS-CoV-2 AMP test kits.
Full Story: Reuters (10/14) 
LinkedIn Twitter Facebook Email
All batches of irbesartan and irbesartan/hydrochlorothiazide tablets from Lupin Pharmaceuticals are being recalled in the US over concerns that they may contain N-nitrosoirbesartan, a potential carcinogen. The Indian firm received four adverse event reports linked to irbesartan use from October 2018 to September 2021.
Full Story: FDAnews (10/18) 
LinkedIn Twitter Facebook Email
Government and Regulatory
Health Care and Policy
The FDA's Vaccines and Related Biological Products Advisory Committee has recommended a second dose of the Johnson & Johnson COVID-19 vaccine for people age 18 and older who received the single-dose vaccine at least two months ago, according to Reuters. Some advisory panel members also asked whether the initial single-dose of the J&J vaccine should be considered a two-dose regimen.
Full Story: Reuters (10/15) 
LinkedIn Twitter Facebook Email
Pfizer and partner BioNTech have announced that they have submitted documentation to the European Medicines Agency on their COVID-19 vaccine to support its use in children between ages 5 to 11. The vaccine has only received authorization in the US and EU for children ages 12 and older.
Full Story: Reuters (10/15) 
LinkedIn Twitter Facebook Email
Company and Financial News
Commercial production of Moderna's COVID-19 vaccine has begun at Samsung Biologics in South Korea, and the South Korean FDA has fast-tracked the company's good manufacturing practice certification application filed in September for domestic distribution. Other countries' regulatory authorities will have to issue GMP certification before Samsung can distribute the vaccines abroad.
Full Story: Pulse by Maeil Business Newspaper (South Korea) (10/15) 
LinkedIn Twitter Facebook Email
How many more times will you watch the full moon rise? Perhaps twenty. And yet it all seems limitless.
Paul Bowles,
writer, composer
LinkedIn Twitter Facebook Email
Aon Home Page  |    Aon Life Sciences
Thought Leadership  |    Media Room
About Aon Life Sciences Practice
Aon provides Life Sciences companies with end-to-end risk solutions, supporting organizations from the initial discovery phase to final product launch. The practice provides solutions across the Life Sciences for pharmaceutical manufacturers; generic and OTC pharmaceutical companies; biotechnology and biopharmaceutical companies; genomic and proteomic companies; drug delivery system; diagnostic substance companies; and medical device and equipment manufacturers.

Contact Aon
Aon Risk Solutions – Life Sciences
James Walters, Global Practice Leader

 Linkedin Twitter
About Aon
Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Unsubscribe  |    Privacy policy
Powered By SmartBrief
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004